

J.S.
fileDEPARTMENT OF THE AIR FORCE
USAF MEDICAL CENTER, WRIGHT-PATTERSON (AFLC)
WRIGHT-PATTERSON AIR FORCE BASE, OHIO 45433REPLY TO
ATTN OF:

SGIII

13 March 1976

SUBJECT:

Progress Report: Clinical Investigation Proposal #634

TO: HQ USAF/SCPR

1. $^{99m}\text{Tc-HSA}$ is being produced by the electrolytic method using the instrumentation provided by New England Nuclear. When injected into patient, and with the use of a special gating device available in our laboratory, we can image the cardiac chambers (mainly the left ventricle) in both systole and diastole. In this way we can diagnose areas of akinesis, aneurysms as well as assess cardiac function by calculating stroke volume and ejection fraction. Since it's approval we have performed 11 such studies. Correlation with the clinical picture, echocardiograms and angiography are very good.
2. No special funds have been allotted for the study.
3. The study will be continued until $^{99m}\text{Tc-HSA}$ is no longer an investigational drug and it becomes a well accepted procedure.
4. The consent form for this project has been changed as requested in the letter of 13 Jun 75 from DGen Ernest J. Clark's office, to mention that $^{99m}\text{Tc-HSA}$ is an investigative new drug that has been approved for limited testing by the Food and Drug Administration.

*John J. Halki*JOHN J. HALKI, Colonel, USAF, MC
CommanderCopy to: AFLC/SG
AND/RD*AFLC - Lifeline of the Aerospace Team*